Piemonte
In Piedmont region 65% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 69 cases of cervicocarcinoma and 29 related deaths and thus results to be cos...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2008-09-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/999 |
| id |
doaj-25fe59b180d74bcba4f283d0fbaa65c6 |
|---|---|
| record_format |
Article |
| spelling |
doaj-25fe59b180d74bcba4f283d0fbaa65c62020-11-25T01:23:39ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2008-09-0191S111310.7175/fe.v9i1S.999935PiemonteMaria Caterina Cavallo0Filippo Cipriani1Simone Gerzeli2Nadia Demarteau3Alessia Marocco4Francesco Bamfi5Università Bocconi, MilanoGlaxoSmithKline Spa, VeronaDipartimento di Statistica ed Economia Applicate L. Lenti, Università di PaviaGlaxoSmithKline Biologicals, Wavre (Belgio)GlaxoSmithKline Spa, VeronaGlaxoSmithKline Spa, VeronaIn Piedmont region 65% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 69 cases of cervicocarcinoma and 29 related deaths and thus results to be cost-effective (24.955 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 66 cancer cases and 28 deaths could be prevented, with a very similar cost-effectiveness ratio. In Piedmont region, the net cost for woman vaccinated is 187 € for the single cohort and 190 € for the multiple cohort.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/999piedmonthpv vaccinationeconomic & clinical impact |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Maria Caterina Cavallo Filippo Cipriani Simone Gerzeli Nadia Demarteau Alessia Marocco Francesco Bamfi |
| spellingShingle |
Maria Caterina Cavallo Filippo Cipriani Simone Gerzeli Nadia Demarteau Alessia Marocco Francesco Bamfi Piemonte Farmeconomia: Health Economics and Therapeutic Pathways piedmont hpv vaccination economic & clinical impact |
| author_facet |
Maria Caterina Cavallo Filippo Cipriani Simone Gerzeli Nadia Demarteau Alessia Marocco Francesco Bamfi |
| author_sort |
Maria Caterina Cavallo |
| title |
Piemonte |
| title_short |
Piemonte |
| title_full |
Piemonte |
| title_fullStr |
Piemonte |
| title_full_unstemmed |
Piemonte |
| title_sort |
piemonte |
| publisher |
SEEd Medical Publishers |
| series |
Farmeconomia: Health Economics and Therapeutic Pathways |
| issn |
2240-256X |
| publishDate |
2008-09-01 |
| description |
In Piedmont region 65% of women (aged 25-64) are screened regularly, meaning every 3 years.
Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 69 cases of cervicocarcinoma and 29 related deaths and thus results to be cost-effective (24.955 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 66 cancer cases and 28 deaths could be prevented, with a very similar cost-effectiveness ratio. In Piedmont region, the net cost for woman vaccinated is 187 € for the single cohort and 190 € for the multiple cohort. |
| topic |
piedmont hpv vaccination economic & clinical impact |
| url |
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/999 |
| work_keys_str_mv |
AT mariacaterinacavallo piemonte AT filippocipriani piemonte AT simonegerzeli piemonte AT nadiademarteau piemonte AT alessiamarocco piemonte AT francescobamfi piemonte |
| _version_ |
1725120864306855936 |